Buspirone vs SSRIs vs Benzodiazepines for Anxiety: What the Evidence Says

The Short Answer

For Generalised Anxiety Disorder (GAD), three main medication classes are prescribed in Australia: SSRIs (the default first-line), benzodiazepines (widely used in practice despite guideline reservations), and buspirone (underutilised despite a comparable evidence base).

Each has a distinct efficacy profile, side effect burden, and risk trajectory — and those differences matter considerably when the patient is a personal injury claimant with a complex, long-term medication history.

Benzodiazepines: Widely Used, Poorly Suited to Long-Term Anxiety

Clinical guidelines position benzodiazepines as a short-term bridge for acute anxiety, not a maintenance treatment for GAD. In practice, the picture is quite different.

Benzos work immediately. Patients feel the effect within minutes, and that rapid relief creates a powerful feedback loop for both the patient and the prescriber. Repeat scripts follow. What begins as a short-term measure frequently becomes a long-term prescription — and that is where the risk profile compounds.

The documented risks of long-term benzodiazepine use include:

• Physical dependence developing within weeks of regular use
• Tolerance, meaning the same dose produces diminishing relief over time
• Cognitive impairment — particularly relevant in older patients, where the effects on memory and processing speed are well-established
• Sedation and fall risk, a significant concern in injured patients with mobility limitations
• Rebound anxiety on cessation that can exceed the original presentation in severity
• Withdrawal syndrome requiring careful tapering, particularly with longer-acting agents

The clinical case for long-term benzo prescribing in GAD is weak. The clinical reality of how difficult they are to cease — and how much harm accumulates in the interim — is well-documented. These are not edge cases. They are common referral presentations for the IMM pharmacist team.

SSRIs: The Default First-Line, For Good Reason

Selective serotonin reuptake inhibitors remain the guideline-recommended first-line treatment for GAD, and the evidence base supporting that position is solid.

Where SSRIs perform well:

• Broad spectrum: SSRIs are effective across multiple anxiety and depressive disorders — panic disorder, social anxiety, OCD, PTSD, and major depression. A patient with comorbid presentations benefits from a single agent addressing multiple targets.
• Once-daily dosing: Adherence is straightforward, and once-daily regimens are consistently associated with better long-term medication compliance.
• PBS listing: SSRIs are significantly cheaper for Australian patients compared to non-PBS medications, which matters for long-term claims where cost-related non-adherence is a real risk.
• Prescriber familiarity: GPs have high confidence with SSRIs, which translates into better monitoring and counselling in practice.

Where SSRIs create clinical challenges:

• Sexual dysfunction: One of the most common reasons patients quietly discontinue SSRIs. Reported rates vary but consistently represent a significant adherence barrier across studies.
• Weight gain: Variable by agent, but a genuine concern particularly with paroxetine and prolonged use of escitalopram and sertraline.
• Emotional blunting: Patients frequently describe a flattening of emotional response that, while distinct from sedation, affects quality of life and treatment satisfaction.
• Initial anxiety spike: SSRIs can worsen anxiety in the first one to two weeks of treatment. For an already-anxious patient, this is a meaningful barrier to initiation and a driver of early discontinuation.
• Discontinuation syndrome: Particularly with paroxetine and venlafaxine, stopping SSRIs requires careful tapering. Discontinuation symptoms — dizziness, "brain zaps", irritability, flu-like symptoms — can be significant and prolonged.

Buspirone: Underutilised, Underrated

Buspirone is a non-benzodiazepine anxiolytic with a mechanism distinct from both SSRIs and benzos. It acts as a serotonin 5-HT1A receptor partial agonist and does not carry the dependence, sedation, or interaction profile of benzodiazepines.

For GAD specifically, multiple studies and meta-analyses demonstrate broadly equivalent efficacy to SSRIs in overall anxiety reduction, with response rates around 60 to 70% for both.

The buspirone advantage profile:

• No dependence or tolerance: Unlike benzodiazepines, buspirone does not produce physical dependence. It can be ceased without a tapering protocol.
• No sedation: Buspirone does not cause the cognitive blunting or sedation associated with benzos, which is particularly relevant for patients managing return-to-work goals.
• No sexual dysfunction: A significant differentiator from SSRIs, and a meaningful reason patients stay on it.
• No weight gain: No clinically significant effect on weight across the evidence base.
• No initial anxiety spike: Unlike SSRIs, buspirone does not worsen anxiety in the early weeks of treatment. This makes initiation easier for anxious patients.
• Lower serotonin syndrome risk: Relevant in complex polypharmacy cases where multiple serotonergic agents are already prescribed.
• Cognitive clarity: Patients frequently report feeling more like themselves — present, clear-headed, and emotionally available — compared to their experience on SSRIs or benzos.

Where buspirone falls short:

• Narrow indication: Evidence is strongest for GAD. Buspirone does not have the same evidence base for panic disorder, social anxiety, OCD, or PTSD.
• Twice to three times daily dosing: Adherence is harder to maintain compared to a once-daily SSRI.
• No PBS listing in Australia: The out-of-pocket cost is a real barrier and the primary reason buspirone is rarely considered by prescribers who are already comfortable with PBS-listed alternatives.
• Slower onset: Unlike benzos, buspirone does not provide immediate relief. It requires consistent use over several weeks before full effect is apparent — a difficult sell for patients seeking rapid relief.

The Benzo Caveat That Changes Clinical Decision-Making

A well-replicated finding in the buspirone literature is that it tends to underperform in patients who have previously taken benzodiazepines — not because it stops working, but because of how patients interpret the experience.

Benzodiazepines set a high subjective threshold. Patients feel strongly sedated and read that sedation as the medication "working." When they switch to buspirone and experience clear-headed anxiety relief without sedation, they interpret the absence of that heaviness as the new medication failing — even when objective measures show anxiety is improving.

Head-to-Head Comparison

Why This Matters in Personal Injury Claims

Anxiety is one of the most common comorbidities in personal injury claimants. It is also one of the most frequently medicated conditions in this population — often with agents that introduce their own downstream risks.

In workers' compensation and CTP claims, a claimant taking a benzodiazepine for GAD is not simply being managed for anxiety. That prescription sits alongside opioids, sleep medications, muscle relaxants, and anticonvulsants. The interaction profile across those medications creates a compounding risk that does not show up unless someone reviews the full list with clinical expertise.

The questions a structured pharmacy review asks of an anxiety prescription include:

• Is the medication appropriate for the specific anxiety presentation, or was it prescribed on pattern?
• Is the duration of use consistent with guidelines, or has a short-term script become indefinite?
• Are there CNS depressant interactions with other medications on the claim that create an additive risk profile?
• If the patient is on a benzodiazepine, has tolerance been discussed? Has a tapering plan been considered?
• Is there a clinically appropriate alternative — such as an SSRI or buspirone — that would achieve the therapeutic goal without the same risk burden?

These are not questions a busy GP appointment is structured to answer. They are exactly what a pharmacy review is designed to surface.

Bottom Line for Insurers and Case Managers

Anxiety prescribing in personal injury claims is not a single-medication problem. It sits at the intersection of clinical complexity, prescriber habit, patient preference, and system access barriers. The result is that the medication with the best long-term risk profile is often the least prescribed, while the one with the worst risk profile for ongoing use remains the most common.

A structured pharmacy review does not override clinical judgment. It informs it — providing the insurer, the treating GP, and the claimant with a clear picture of what is being prescribed, why, whether it is appropriate, and what alternatives exist. In a population where medication complexity is the norm, that clinical intelligence layer has a direct impact on claim trajectory.